Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA
Executive Summary
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
You may also be interested in...
FDA, CDC Leaders Under Trump Urge Fixed Terms For US Health Agency Heads
Former FDA Commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.
Hahn Urges Fixed Terms For US FDA Leaders
Former commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.
Capitol Hill Riot Draws Manufacturing Group’s Call For Trump’s Removal
PhRMA and BIO are members of the National Association of Manufacturers, which made the statement urging the 25th amendment be invoked.